Clinical Trial Update: Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for RGN-259 ophthalmic solutions evaluating safety and efficacy in Dry Eye Syndrome across Phase 2 and Phase 3 (ARISE-1) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Syndrome

Drugs mentioned

• RGN-259 ophthalmic solutions (RGN-259 ophthalmic solution)

Snippet

Sponsor: ReGenTree, LLC | Conditions: Dry Eye Syndrome | Phase 2, Phase 3 | Status: COMPLETED